Skip to main content

Minocycline Gel May Be Effective for Rosacea

Minocycline gel was associated with improvements in the signs and symptoms of papulopustular rosacea, according to the findings of a recent study.

In the prospective, double-blind study, 270 participants with papulopustular rosacea at 26 sites across the United States were randomized to either 1% minocycline, 3% minocycline, or vehicle. They applied the topical treatment to their face at bedtime for 12 weeks. Primary endpoints included the mean change in inflammatory lesions at week 12, and success on the Investigator Global Assessment (IGA).

The mean lesion count was 24.6 in the 1% minocycline group, 25.1 in the 3% minocycline group, and 24.3 in the vehicle group at baseline.
____________________________________________________
You may also like...

Diagnosing Rosacea in the Hispanic Patient
Combination Therapy Effectively Treats Rosacea
____________________________________________________

After 12 weeks of treatment, the lesion count decreased by 12.64, 13.09, and 7.92 among the 1% minocycline, 3% minocycline, and vehicle groups, respectively, the researchers said. Compared with vehicle, both 1% and 3% minocycline were associated with significantly decreased inflammatory lesions, they added.

The proportion of participants who achieved IGA success was 38.9%, 46.2%, and 30.8% in the 1% minocycline, 3% minocycline, and vehicle groups. A significantly larger proportion of participants achieved IGA success after 12 weeks in the 3% minocycline group, the researchers observed.

“These findings support further evaluation of minocycline gel for the treatment of inflammatory lesions associated with papulopustular rosacea,” they concluded.

Reference

Webster G, Draelos ZD, Graber E, et al. A multicenter, randomized, double‐masked, parallel group, vehicle‐controlled phase 2b study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea [published online January 6, 2020]. Br J Dermatol. doi:10.1111/bjd.18857

Back to Top